| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | 20016 |
| Drug | House Dust Mite Extract |
| Brand | Acarizax ® |
| Indication | Is indicated in adult patients (18-65 years) with HDM allergic asthma not well controlled by inhaled corticosteroids (ICS) and associated with mild to severe house dust mite allergic rhinitis. Diagnosis should be confirmed by clinical history and a positive test of HDM sensitisation (skin prick test and/or specific IgE). |
| Assessment Process | |
| Rapid review commissioned | 12/03/2020 |
| Rapid review completed | 30/04/2020 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of HDM extract (Acarizax ®) for allergic asthma compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 07/05/2020 |
| Pre-submission consultation with Applicant | 08/06/2020 |
| Full submission received from Applicant | 28/04/2022 |
| Preliminary review sent to Applicant | 26/09/2022 |
| NCPE assessment re-commenced | 08/11/2022 |
| Factual accuracy sent to Applicant | 20/01/2023 |
| NCPE assessment re-commenced | 27/01/2023 |
| NCPE assessment completed | 24/02/2023 |
| NCPE assessment outcome | The NCPE recommends that House Dust Mite extract (Acarizax®) not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.